Journal
EUROPEAN HEART JOURNAL
Volume 36, Issue 24, Pages 1512-U92Publisher
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehv114
Keywords
Heme oxygenase pathway; Carbon monoxide; Bilirubin; Biliverdin; Cardiovascular disease
Categories
Funding
- Ellison Foundation
- NIH/NHLBI [R01HL114839, R03HL115106, P01HL108801, R00HL107642]
Ask authors/readers for more resources
Evidence now points to the haeme oxygenase (HO) pathway as a possible actor in modulating risk for cardiovascular disease (CVD). In particular, the HO pathway may represent a key endogenous modulator of oxidative, inflammatory, and cytotoxic stress while also exhibiting vasoregulatory properties. In this review, we summarize the accumulating experimental and emerging clinical data indicating how activity of the HO pathway and its products may play a role in mechanisms underlying the development of CVD. We also identify gaps in the literature to date and suggest future directions for investigation. Because HO pathway activity can be influenced not only by genetic traits and environmental stimuli but also by a variety of existing pharmacologic interventions, the pathway could serve as a prime target for reducing the overall burden of CVD. Further work is needed to determine the role of HO pathway products as possible prognostic markers of risk for clinical CVD events and the extent to which therapeutic augmentation or inhibition of HO pathway activity could serve to modify CVD risk.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available